Lymphoma

>

Latest News

Lower Rates of ICANS, CRS 2 Weeks After CAR T May Support Shorter Monitoring Period for DLBCL
Lower Rates of ICANS, CRS 2 Weeks After CAR T May Support Shorter Monitoring Period for DLBCL

July 25th 2024

The monitoring period after CAR T-cell therapy may be safe if shortened due to the lower incidence of ICANS and CRS 2 weeks after treatment in patients with DLBCL.

Ibrutinib-Venetoclax Combo Elicits Durable Complete Responses in TP53+ MCL
Ibrutinib-Venetoclax Combo Elicits Durable Complete Responses in TP53+ MCL

July 24th 2024

Brentuximab Vedotin Triplet Provides Stronger Survival Signal vs R2 in R/R DLBCL
Brentuximab Vedotin Triplet Provides Stronger Survival Signal vs R2 in R/R DLBCL

July 22nd 2024

Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL

July 15th 2024

Ibrutinib Plus Chemoimmunotherapy Induction Improves Failure-Free Survival in Young Patients With MCL
Ibrutinib Plus Chemoimmunotherapy Induction Improves Failure-Free Survival in Young Patients With MCL

July 6th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.